These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31612773)

  • 1. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges.
    Nunes R; Neves JD; Sarmento B
    Nanomedicine (Lond); 2019 Oct; 14(19):2631-2644. PubMed ID: 31612773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
    Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
    Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease.
    Kotla NG; Singh R; Baby BV; Rasala S; Rasool J; Hynes SO; Martin D; Egan LJ; Vemula PK; Jala VR; Rochev Y; Pandit A
    Biomaterials; 2022 Feb; 281():121364. PubMed ID: 35066288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients.
    Schmidt C; Lautenschlaeger C; Collnot EM; Schumann M; Bojarski C; Schulzke JD; Lehr CM; Stallmach A
    J Control Release; 2013 Jan; 165(2):139-45. PubMed ID: 23127508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmaceutical strategies for efficient site specific delivery in inflamed distal intestinal mucosa.
    Sharma S; Sinha VR
    J Control Release; 2018 Feb; 272():97-106. PubMed ID: 29317245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model.
    Melero A; Draheim C; Hansen S; Giner E; Carreras JJ; Talens-Visconti R; Garrigues TM; Peris JE; Recio MC; Giner R; Lehr CM
    Eur J Pharm Biopharm; 2017 Oct; 119():361-371. PubMed ID: 28709903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injected laquinimod D-α-tocopheryl polyethylene glycol-1000 succinate polymeric micelles for the treatment of inflammatory bowel disease.
    Wang L; Xue P; Tong M; Chen R; Yang W; ZhuGe D; Yuan J; Yao Q; Zhao Y; Xu H
    Colloids Surf B Biointerfaces; 2020 Jan; 185():110575. PubMed ID: 31670003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
    Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
    Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Uptake Into Inflamed Human Intestinal Tissue and Immune Cell Targeting by Wormlike Polymer Micelles.
    Gardey E; Cseresnyes Z; Sobotta FH; Eberhardt J; Haziri D; Grunert PC; Kuchenbrod MT; Gruschwitz FV; Hoeppener S; Schumann M; Gaßler N; Figge MT; Stallmach A; Brendel JC
    Small; 2024 May; 20(21):e2306482. PubMed ID: 38109123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
    Szewczuk MR; Depew WT
    Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery nano/micro particles to inflamed intestinal mucosa in human.
    Park K
    J Control Release; 2013 Jan; 165(2):162. PubMed ID: 23265297
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa.
    Dar MJ; Ali H; Khan A; Khan GM
    J Drug Target; 2017 Aug; 25(7):582-596. PubMed ID: 28277824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting.
    Bertoni S; Machness A; Tiboni M; Bártolo R; Santos HA
    Biopolymers; 2020 Jan; 111(1):e23336. PubMed ID: 31724750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
    Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
    J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
    Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
    Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.